

## paroxetine 7.5 mg capsule

### Disclaimer

*Clinical guidelines are developed and adopted to establish evidence-based clinical criteria for utilization management decisions. Clinical guidelines are applicable according to policy and plan type. The Plan may delegate utilization management decisions of certain services to third parties who may develop and adopt their own clinical criteria.*

*Coverage of services is subject to the terms, conditions, and limitations of a member's policy, as well as applicable state and federal law. Clinical guidelines are also subject to in-force criteria such as the Centers for Medicare & Medicaid Services (CMS) national coverage determination (NCD) or local coverage determination (LCD) for Medicare Advantage plans. Please refer to the member's policy documents (e.g., Certificate/Evidence of Coverage, Schedule of Benefits, Plan Formulary) or contact the Plan to confirm coverage.*

paroxetine 7.5 mg capsule	1
Summary	2
Definitions	2
Clinical Indications	3
Medical Necessity Criteria for Clinical Review	3
General Medical Necessity Criteria	3
Medical Necessity Criteria for Initial Clinical Review	3
Initial Indication-Specific Criteria	3
Vasomotor symptoms associated with menopause (VMS)	3
Medical Necessity Criteria for Subsequent Clinical Review	3
Subsequent Indication-Specific Criteria	3
Vasomotor symptoms associated with menopause (VMS)	3
Experimental or Investigational / Not Medically Necessary	4
References	4
Clinical Guideline Revision / History Information	5

## Summary

Vasomotor symptoms (VMS), including hot flashes and night sweats, are common symptoms of menopause that can significantly impact quality of life. They are caused by the decline in estrogen levels during the menopausal transition. Systemic menopausal hormone therapy (MHT) with estrogen, with or without progestin, is the most effective treatment for VMS. However, MHT may not be appropriate for all women, such as those with a history of breast cancer, cardiovascular disease, venous thromboembolism, a history of stroke, or active liver disease. Nonhormonal treatment options for VMS include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other medications like gabapentin, clonidine and oxybutynin.

Paroxetine capsules are a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS). It provides an additional nonhormonal treatment option for women who cannot or choose not to use MHT. The brand Brisdelle is no longer on the market.

Paroxetine capsules have a black box warning for increased risk of suicidal thoughts and behaviors. Monitor for worsening and emergence of suicidal thoughts and behaviors.

## Definitions

"Documentation" refers to written information, including but not limited to:

1. Up-to-date chart notes, relevant test results, and/or relevant imaging reports to support diagnoses;
2. Prescription claims records, and/or prescription receipts to support prior trials of formulary alternatives.

"Menopause" refers to the point in time 12 months after a woman's last menstrual period, marking the end of the menopausal transition.

"No evidence of" indicates that the reviewer has not identified any records of the specified item or condition within the submitted materials or claims history. In the absence of such evidence, the member is considered eligible. If any evidence of the item or condition is present upon review of the request, the applicant does not qualify.

"Perimenopause" is the menopausal transition, a span of time starting when a woman begins experiencing menstrual irregularity through 12 months after the final menstrual period.

"Postmenopause" refers to the time after menopause has occurred, starting 12 months after the final menstrual period.

"Vasomotor symptoms (VMS)" refer to hot flashes (sensations of heat, sweating, flushing) and night sweats associated with the menopausal transition.

"[s]" indicates state mandates may apply.

## Clinical Indications

### Medical Necessity Criteria for Clinical Review

#### General Medical Necessity Criteria

The Plan considers paroxetine 7.5 mg capsule medically necessary when ALL of the following criteria are met:

1. The member is a menopausal woman; *AND*
2. The member meets ALL of the following:
  - a. No evidence of concurrent use with monoamine oxidase inhibitors (MAOI) or use within 14 days of MAOI use; *and*
  - b. No evidence of use with thioridazine; *and*
  - c. No evidence of use with pimozide; *AND*
3. Paroxetine 7.5 mg capsule is being prescribed at a dose and frequency that is within FDA approved labeling OR is supported by compendia or evidence-based published dosing guidelines for the requested indication.  
*The requested medication is being used within the Plan's Quantity Limit of: 1 capsule per day (30 capsules per 30 days).*
4. The member meets the applicable [Medical Necessity Criteria for Initial Clinical Review](#) or [Subsequent Clinical Review](#) listed below.

### Medical Necessity Criteria for Initial Clinical Review

#### Initial Indication-Specific Criteria

##### Vasomotor symptoms associated with menopause (VMS)

The Plan considers paroxetine 7.5 mg capsule medically necessary when ALL of the following criteria are met:

1. The member meets the above [General Medical Necessity Criteria](#); *AND*
2. The member is experiencing moderate to severe vasomotor symptoms.

If the above prior authorization criteria are met, the requested product will be authorized for up to 12-months.<sup>[s]</sup>

*Continued Care*

**Medical Necessity Criteria for Subsequent Clinical Review**

Subsequent Indication-Specific Criteria

**Vasomotor symptoms associated with menopause (VMS)**

The Plan considers paroxetine 7.5 mg capsule medically necessary when ALL of the following criteria are met:

1. The member meets the above applicable **General Medical Necessity Criteria**; **AND**
2. Clinically significant reduction in the frequency and/or severity of VMS from baseline, such as:
  - a. Reduction in the frequency of moderate to severe hot flashes; **or**
  - b. Reduction in the symptomatic severity of hot flashes; **or**
  - c. Improvement in VMS-related quality of life, sleep, or other member-reported outcomes; **AND**
3. The member continues to experience moderate to severe vasomotor symptoms (VMS, or hot flashes) associated with menopause that warrant ongoing treatment; **AND**
4. There is no evidence of unacceptable toxicity or adverse reactions to paroxetine 7.5 mg capsule.

If the above reauthorization criteria are met, the requested product will be authorized for up to 12-months.<sup>[s]</sup>

**Experimental or Investigational / Not Medically Necessary<sup>[s]</sup>**

Paroxetine 7.5 mg capsule for any other indication or use is considered not medically necessary by the Plan, as it is deemed to be experimental, investigational, or unproven. Non-covered indications include, but are not limited to, the following:

- Use in perimenopausal women (before menopause has been reached), as efficacy and safety have not been established in this population.
- Use for treatment of mild VMS, as pivotal trials only included women with moderate to severe VMS defined as  $\geq 7$  moderate to severe hot flashes per day or  $\geq 50$  per week.
- Use for psychiatric conditions. Paroxetine capsules are a selective serotonin reuptake inhibitor (SSRI); however, it is not indicated for the treatment of any psychiatric condition. Paroxetine capsules contain a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. Those who require paroxetine for treatment of a psychiatric condition should discontinue paroxetine capsules and initiate a paroxetine-containing medication that is indicated for such use.

**References**

1. "The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2023 nonhormone therapy position statement of The North

American Menopause Society. Menopause. 2023 Jun 1;30(6):573-590. doi: 10.1097/GME.0000000000002200. PMID: 37252752.

2. "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022 Jul 1;29(7):767-794. doi: 10.1097/GME.0000000000002028. PMID: 35797481.
3. Arinkan, S.A. and Gunacti, M. (2021), Factors influencing age at natural menopause. *J. Obstet. Gynaecol. Res.*, 47: 913-920. <https://doi.org/10.1111/jog.14614>.
4. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. *Climacteric*. 2016 Apr;19(2):109-50. doi: 10.3109/13697137.2015.1129166. Epub 2016 Feb 12.
5. Brisdelle (paroxetine) [prescribing information]. George Town, Grand Cayman: Legacy Pharma Inc; April 2025.
6. Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. American Association Of Clinical Endocrinologists And American College Of Endocrinology Position Statement On Menopause-2017 Update. *Endocr Pract*. 2017 Jul;23(7):869-880. doi: 10.4158/EP171828.PS. Erratum in: *Endocr Pract*. 2017 Dec;23 (12):1488. PMID: 28703650.
7. Drugs for Menopausal Symptoms. *JAMA*. 2021;325(23):2394–2395. doi:10.1001/jama.2020.15592
8. Flores VA, Pal L, Manson JE. Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment. *Endocr Rev*. 2021 Nov 16;42(6):720-752. doi: 10.1210/endrev/bnab011. PMID: 33858012.
9. Khan AA, Alrob HA, Ali DS, et al. Guideline No. 422g: Menopause and Osteoporosis. *J Obstet Gynaecol Can*. 2022 May;44(5):527-536.e5. doi: 10.1016/j.jogc.2021.09.013.
10. Langer, R. D., Hodis, H. N., Lobo, R. A., & Allison, M. A. (2021). Hormone replacement therapy – where are we now? *Climacteric*, 24(1), 3–10. <https://doi.org/10.1080/13697137.2020.1851183>.
11. Melissa A. McNeil, Sarah B. Merriam. Menopause. *Ann Intern Med*.2021;174:ITC97-ITC112. [Epub 13 July 2021]. doi:10.7326/AITC202107200.
12. Menopause: identification and management: Evidence review G. London: National Institute for Health and Care Excellence (NICE); 2024 Nov.
13. Rees M, Abernethy K, Bachmann G, et al. The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement. *Maturitas*. 2022 Apr;158:70-77. doi: 10.1016/j.maturitas.2021.12.001. Epub 2022 Feb 1.
14. Salvatore, S., Benini, V., Ruffolo, A. F., Degliuomini, R. S., Redaelli, A., Casiraghi, A., & Candiani, M. (2023). Current challenges in the pharmacological management of genitourinary syndrome of menopause. *Expert Opinion on Pharmacotherapy*, 24(1), 23–28. <https://doi.org/10.1080/14656566.2022.2152326>.
15. Stuenkel CA, Davis SR, Gompel A, et AL. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. 2015 Nov;100(11):3975-4011. doi: 10.1210/jc.2015-2236. Epub 2015 Oct 7.
16. US Preventive Services Task Force. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. *JAMA*. 2022;328(17):1740–1746. doi:10.1001/jama.2022.18625

#### Clinical Guideline Revision / History Information

Original Date: 01/01/2026

Reviewed/Revised: